A practical approach to risk assessment to prevent coronary artery disease and its complications (Q35179558)

7 August 2017

1 reference

title

A practical approach to risk assessment to prevent coronary artery disease and its complications (English)

1 reference

7 August 2017

1 reference

coronary artery disease

1 reference

MacRae F Linton

1

1 reference

7 August 2017

Sergio Fazio

series ordinal

2

1 reference

7 August 2017

National Cholesterol Education Program (NCEP)- the third Adult Treatment Panel (ATP III)

series ordinal

3

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

American Journal of Cardiology

7 August 2017

1 reference

7 August 2017

92

1 reference

7 August 2017

1A

1 reference

7 August 2017

19i-26i

1 reference

Cardiovascular disease risk profiles.

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Established and emerging cardiovascular risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Primary prevention of coronary heart disease in women through diet and lifestyle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

The relationship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Trial (MRFIT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Blood pressure, stroke, and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Final report on the aspirin component of the ongoing Physicians' Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Current perspectives on statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Hypertriglyceridemia as a cardiovascular risk factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

LDL size and risk of coronary heart disease in elderly men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Lipoprotein(a) as a risk factor for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Homocysteine and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

On evolutionary biology, inflammation, infection, and the causes of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Plasminogen-activator inhibitor type 1 and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Cardiovascular morbidity and mortality associated with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Indications for cholesterol-lowering medication: comparison of risk-assessment methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

New tools for coronary risk assessment: what are their advantages and limitations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Prevention Conference V : Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Noninvasive Tests of Atherosclerotic Burden : Writing Group III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Family history of heart attack as an independent predictor of death due to cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Frequency of coronary heart disease and cerebrovascular accidents in parents and sons of coronary heart disease index cases and controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Familial aggregation of coronary heart disease in a high incidence area (North Karelia, Finland)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Measurement error from assessing use of vitamin supplements at one point in time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

Fibrinogen and its degradation products as thrombotic risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900505-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(03)00505-8

1 reference

7 August 2017

1 reference